Mutational Processes Molding the Genomes of 21 Breast CancersSerena Nik‐Zainal, Michael S. Neuberger, Ludmil B. Alexandrov et al.|Cell|2012Cited by 2k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, James Carmichael, Mark E. Robson et al.|The Lancet|2010Cited by 1.6k
Molecular Definition of Breast Tumor HeterogeneityMichail Shipitsin, Kornélia Polyák, Lauren L. Campbell et al.|Cancer Cell|2007Cited by 1.4k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017Giuseppe Curigliano, Andrew Tutt, Harold J. Burstein et al.|Annals of Oncology|2017Cited by 1.3k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast CancerMelinda L. Telli, Andrea L. Richardson, Kirsten M. Timms et al.|Clinical Cancer Research|2016Cited by 1.2k